Actively Recruiting
Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Led by Centre Hospitalier Universitaire Dijon · Updated on 2026-04-02
200
Participants Needed
2
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Currently, the exploration of primary hemostasis (a physiological phenomenon used to stop bleeding) is imperfect because it is based on targeted tests for platelets or von Willebrand factor, without taking into account blood flow and other blood cells (red and white blood cells). Tests for whole blood and flow conditions exist, but there is currently no test that comes close to actual physiological conditions. An exploration of whole blood haemostasis in a device that is similar to a blood vessel and at different flow conditions (venous and arterial) could help to better identify the risk of bleeding in predisposed patients (von Willebrand factor deficiency, antiplatelet therapy). The objective of the study is to evaluate the performance of this new hemostasis test in whole blood and under flow conditions. Participation in the study is ad hoc and is limited to adding a maximum of 4 citrated tubes (20 mL or the equivalent of 4 teaspoons) and 1 EDTA tube (5mL) to a routine blood sample (for patients) or during blood donation (for controls).
CONDITIONS
Official Title
Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Person who has given oral consent
- Adult
- Blood donor at EFS Bourgogne Franche-Comté
- Patient with von Willebrand disease or major constitutional thrombopathy followed by the Resource and Competence Centre (CRC) - Constitutional Hemorrhagic Diseases of Dijon or Besançon
- Patient on antiplatelet drugs consulting for thrombosis at the Dijon Bourgogne or Besançon Hospital
You will not qualify if you...
- Not affiliated to or not a beneficiary of national health insurance
- Subject to court-ordered protection (curatorship, guardianship)
- Pregnant, parturient, or breastfeeding woman
- Unable to consent
- On anti-inflammatory treatment and serotonin reuptake inhibitor antidepressants (platelet function disorders)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
CHU de Besançon
Besançon, France
Actively Recruiting
2
CHU Dijon Bourgogne
Dijon, France
Actively Recruiting
Research Team
E
Emmanuel De Maistre
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here